Novartis’ Zolgensma shows ‘continued benefit’ in SMA patients
66.7% of patients in the intent-to-treat population were able to feed orally without the need for feeding support
Read More
Tag: onasemnogene abeparvovec
EU approves Novartis’ SMA gene therapy Zolgensma
Discussions with EU governments and reimbursement agencies are ongoing to agree on terms of an innovative ‘Day One’ access programme
Read More
Novartis’ SMA therapy gets US priority review
US regulators have accepted for review Novartis’ Biologics License Application for Zolgensma, an investigational gene replacement therapy for the treatment of spinal muscular atrophy (SMA) Type 1.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
